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Invasive group A Streptococcus (GAS) infections can
be fatal and can occur in healthy children. A case-control
study identified factors associated with pediatric disease.
Case-patients were identified when Streptococcus pyo-
genes was isolated from a normally sterile site, and
matched controls (>2) were identified by using sequential-
digit dialing. All participants were noninstitutionalized sur-
veillance-area residents <18 years of age. Conditional
regression identified factors associated with invasive dis-
ease: other children living in the home (odds ratio [OR] =
16.85, p = 0.0002) and new use of nonsteroidal antiinflam-
matory drugs (OR = 10.64, p = 0.005) were associated with
increased risk. More rooms in the home (OR = 0.67, p =
0.03) and household member(s) with runny nose (OR =
0.09, p = 0.002) were associated with decreased risk.
Among children, household-level characteristics that influ-
ence exposure to GAS most affect development of invasive
disease.
I
nvasive group A Streptococcus (GAS) infections include
sepsis, bacteremic pneumonia, and dramatic, rapidly pro-
gressive syndromes such as necrotizing fasciitis and strep-
tococcal toxic shock syndrome (STSS). An estimated 9,100
cases and 1,350 deaths occur in the United States each year,
many of these among previously healthy children (1).
Previous studies identified associations between indi-
vidual-level risk factors and pediatric invasive GAS dis-
ease. Many hospital-based case series (2–13) and 2
population-based studies (14,15) have associated varicella-
zoster virus (VZV) infection with an increased risk for
invasive GAS disease. Use of nonsteroidal antiinflamma-
tory drugs (NSAIDs) was also associated (9,12), but
whether NSAID use predisposed to or increased the sever-
ity of GAS infection (16) or was a marker of disease sever-
ity (17) is unclear. These previous studies were limited by
the completeness of the data available from medical and
laboratory records.
Household-level risk factors appear to play a role in
disease development. Studies conducted in the 1950s
demonstrated that school-age children were most often
responsible for introducing a GAS strain into a household
(18). Household transmission of GAS infection facilitated
a communitywide GAS outbreak in southeastern
Minnesota (19). Household crowding, measured by the
number of persons in the home, and exposure to children
with a sore throat in the home have been associated with
increased risk for invasive GAS in adults (20). Household
exposures have not been studied concomitantly with indi-
vidual-level risk factors in children.
We conducted a population-based, case-control study
with parental interviews to concomitantly study and iden-
tify individual- and household-level risk factors for inva-
sive pediatric GAS disease. Parents could provide more
complete data than medical record review. Simultaneous
study of both types of data could also assess the relative
effects of individual and household characteristics. 
Methods
Invasive GAS disease was defined as the isolation of
Streptococcus pyogenes from a normally sterile site
(including blood, cerebrospinal fluid, pleural fluid, peri-
toneal fluid, pericardial fluid, joint fluid, surgical speci-
mens, bone, and scrotal fluid) in a noninstitutionalized
resident, <18 years of age, in a surveillance area. Children
who had GAS isolated from a sterile site >48 hours after
hospital admission were presumed to have a nosocomial
infection (21) and were excluded. 
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active, laboratory-based surveillance in 3 areas: metropol-
itan Atlanta, Georgia, from July 1, 1997, to June 30, 1999;
metropolitan Baltimore, Maryland, from July 1, 1997,
through June 30, 1999; and the Toronto-Peel region,
Ontario, Canada, from July 1, 1997, through December 31,
1997. The surveillance area population was estimated to
include 9 million people (3.6 in metropolitan Atlanta, 2.4
in metropolitan Baltimore, and 3.0 in the Toronto-Peel
region based on 1997 Bureau of Census estimates [22]).
All acute-care hospitals and laboratories serving the resi-
dents of the surveillance area were contacted biweekly and
audited semiannually to identify patients with invasive
GAS disease. For each case of pediatric invasive GAS
identified, the standardized Active Bacterial Core
Surveillance case-report form was completed by reviewing
the hospital medical record. This form is used for all
organisms under surveillance and includes all laboratory
and clinical data needed to fulfill the criteria for strepto-
coccal toxic shock syndrome (STSS) (23) and other clini-
cal syndromes.
The method used to reach case-patients and identify
controls has been described elsewhere (20). Briefly, a
“case algorithm” was used to contact persons infected with
invasive GAS. For each case-patient identified, up to 15
separate telephone calls were made to contact the parent or
guardian. To maximize the likelihood of contacting the
patient, the telephone calls were made on 5 nonconsecu-
tive days, including at least 1 weekend day, during each of
3 different time periods (8:00 a.m.–12:00 p.m., 12:01–5:00
p.m., 5:01–8:00 p.m.). Case-patients were eligible if their
enrollment was complete within 3 months of onset of GAS
disease. Family members of deceased case-patients were
interviewed, and non–English-speaking patients were
included if individual surveillance sites had the resources
to communicate with the patients in their language. 
A population-based sample of matched controls was
selected through systematic, sequential-digit telephone
dialing. Case-patients and controls were matched by age
group, postal or zip code, and telephone exchange to con-
trol for age and socioeconomic status. Age groups were
defined as 0–23 months, 24–59 months, and 5–17 years.
Case-patients without telephones were excluded.
When experienced surveillance personnel reached the
parent or guardian of a case-patient or control, they
explained the purpose of the study, obtained informed con-
sent, and administered a standardized questionnaire. The
questionnaire included questions on demographics, socioe-
conomic status, age-specific activities like breastfeeding
and preschool, medical history, and household characteris-
tics. The household characteristics included physical
space, number of persons in the household, persons who
smoke, and symptoms in other persons in the past 2 weeks
for controls or in the 2 weeks before invasive GAS disease
among case-patients. Within the medical history section,
we differentiated between “regular” NSAID use and
“new” NSAID use. New NSAID use indicated that the
case-patient had started using NSAIDs in the 2 weeks
before illness was diagnosed or that a control participant
had started using NSAIDs in the 2 weeks before the inter-
view. The parent or guardian for case-patients and controls
was allowed to self-define regular use of NSAIDS. This
study was approved by the institutional review boards at
the Centers for Disease Control and Prevention and at each
surveillance site.
Odds ratios (ORs) for each potential risk factor were
determined by using conditional logistic regression (Proc
PHREG, SAS Version 6.12, SAS Institute Inc., Cary, NC,
USA), controlling for sex and race. Variables with p<0.20
in individual analyses were included in multivariable
analysis. Computer-assisted and manual forward, back-
ward, and stepwise conditional logistic regression identi-
fied risk factors independently associated with invasive
GAS disease. ORs with 95% confidence intervals (CIs)
that did not include 1.00 and p values <0.05 were consid-
ered significant in multivariable analysis.
Results
Surveillance identified 72 episodes of invasive GAS
disease among children <18 years of age. Eight had noso-
comial infection and were ineligible. Of the 64 remaining,
38 were enrolled, 5 parents or guardians refused to partic-
ipate, 3 were not reached after exhausting the telephone
call algorithm, and 18 did not participate for other reasons,
including a time lapse of >3 months after the illness,
incomplete or incorrect contact information (i.e., wrong
phone number, disconnected phone, no phone, homeless-
ness), and difficulty communicating over the phone (i.e.,
poor communication skills, non–English-speaking parent
or guardian). No statistical differences in race, sex, age, or
death rate were seen between enrolled and nonenrolled
patients. 
The number of case-patients enrolled varied by area: 20
(53%) from Atlanta, 11 (29%) from Baltimore, and 7
(18%) from Toronto. Ten (26%) patients were 0–23
months of age, 7 (18%) were 24–59 months, and 21 (55%)
were 5–18 years. Forty-seven percent were boys. Of
enrolled patients, 24 (63%) were white, 13 (34%) were
African American, and 1 (3%) did not specify ethnicity.
Two patients (5%) died of the disease; both were diag-
nosed with primary bacteremia without focus. Primary
bacteremia and cellulitis were the 2 most common diag-
noses (Table 1). No cases of STSS were found.
Several factors were associated with invasive GAS dis-
ease (Table 2). When sex and race were controlled for in
individual analysis, having a primary caretaker who
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new use of NSAIDs were associated with an increased risk
for invasive GAS disease (p<0.05); more rooms in the
home, higher level of parental education, and a household
member with a runny nose (rhinitis) in the past 2 weeks
were associated with a decreased risk for invasive GAS
disease (p<0.05). By using multivariable conditional
regression and controlling for sex and race, 4 risk factors
were found to be independently associated with invasive
GAS disease: having >1 other children in the home (OR =
16.85, p = 0.0002) and new use of NSAIDs (OR = 10.64,
p = 0.005) were associated with an increased risk, and
more rooms in the home (OR = 0.67, p = 0.03) and having
a household member with a runny nose in the past 2 weeks
(OR = 0.09, p = 0.002) were associated with a decreased
risk.
VZV and HIV infection occurred only in case-patients
(n = 3 and n = 1, respectively). Patients and controls were
equally likely to be vaccinated against VZV (OR = 0.93, p
= 0.88). Of the 3 case-patients with history of VZV infec-
tion, 1 reported new use of NSAIDs. Among participants
0–23 months of age, 12 (71%) of 17 controls were current-
ly being or had ever been breastfed compared to 0 of 8
case-patients (OR = 0, p = 1.00).
Discussion
This study suggests that children bring GAS into the
home and that crowding, measured by the number of
rooms in the home, influences the development of invasive
GAS disease. The protective association of rhinitis was
unexpected, and the mechanism of protection is not obvi-
ous. Individual-level risk factors seem to play a less impor-
tant role. Although NSAID use is associated with invasive
disease, the measurements of new use and regular use are
too crude to clearly identify their role as a risk factor. 
The roles of children and crowding are expected and
have been suggested by previous studies. Children are
most likely to introduce GAS infection into the home (18),
children spread GAS in the home (19), and children with
sore throats are likely reservoirs of GAS for adults who
develop invasive disease (20). Crowding, measured by
number of people in the home, increases risk for acquiring
disease among adults >45 years of age (20).
Although the association between rhinitis and invasive
GAS infection may be spurious, data support a true rela-
tionship. Among persons with sore throats, those with
rhinitis are less likely to have GAS pharyngitis than are
those without rhinitis (24,25). This finding suggests that
controls were less likely to be exposed to persons with
GAS pharyngitis than were case-patients.
Although only significant in individual analysis in this
study, cigarette smoke has been independently associated
with other invasive bacterial infections in other studies.
Increased risk for invasive meningococcal disease in chil-
dren <18 years is associated with having a mother who
smokes (26), and increased risk for invasive pneumococcal
disease in immunocompetent, nonelderly adults is associ-
ated with both being a smoker and being exposed to other
smokers (27). Larger numbers of case-patients may show
an association.
A large difference was seen in the proportions of
patients and controls who have been breastfed, although
this difference was not significant. Breastfeeding may pro-
tect against invasive GAS disease as it does against other
invasive bacterial diseases. Previous studies found current
breastfeeding protective against invasive pneumococcal
disease in children 2–11 months of age (28) and against
invasive Haemophilus influenzae type B disease in chil-
dren <6 months of age (29). Data suggest that in addition
to containing protective antibodies against these organ-
isms, breast milk can inhibit bacterial colonization inde-
pendent of antibody concentration (30). Although HIV
infection is a risk factor for invasive GAS infection in
adults (20,31) and VZV infection is a risk factor for inva-
sive GAS infection in children (14–15), this study had too
few patients to comment on either.
This study has several limitations. The small size limits
the statistical power to identify associations between indi-
vidual- and household-level characteristics and invasive
GAS disease. Some questions were only asked of sub-
groups, further decreasing power to detect associations.
Using sequential-digit dialing and matching on zip or
postal codes controlled for socioeconomic and communi-
ty-level risk factors. These factors could therefore not be
studied. This method may limit the generalizability of the
findings; the study population included only persons with
phones and, specifically, persons likely to answer their
phones.
The associations in this study all suggest that develop-
ment of pediatric invasive GAS disease is largely related to
opportunities for exposure to GAS, as measured by expo-
sure to children, other persons, and persons with GAS
infections. Individual-level risk factors in children are less
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by their household contacts may be preventive and should
be encouraged.
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